Document:

EX-10.30

 Exhibit 10.30 
 Execution 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY
SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 8 OF THIS WARRANT.

 REVANCE THERAPEUTICS, INC. 
 WARRANT TO PURCHASE SHARES 
 OF SERIES PREFERRED STOCK 

THIS CERTIFIES THAT, for value received and subject to the provisions and upon the terms and conditions set forth in this Warrant,
[            ] and its assignees are entitled to subscribe for and purchase at the Warrant Price that number of the fully paid and nonassessable shares of Series Preferred Stock of
REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), as is equal to the nearest whole number derived from dividing $360,000 by the Warrant Price. 

1. Definitions. As used herein, capitalized terms not otherwise defined herein shall have the following respective meanings:

 (a) “Act” means the Securities Act of 1933, as amended. 

(b) “Common Stock” means the Common Stock of the Company. 

(c) “Common Stock Equivalents” means, (i) with respect to any Convertible Security, the number of shares of
Common Stock that would result from full conversion, exercise or exchange of a Convertible Security in one or more steps, and (ii) with respect to a Unit, the number of shares of Common Stock resulting after aggregating all Common Stock and
Common Stock Equivalents underlying Convertible Securities which are contained within a Unit. 
 (d) “Convertible
Security” means (i) any stock or securities directly or indirectly convertible into or exchangeable for Common Stock and (ii) any rights, warrants or options to subscribe for or purchase Common Stock or stock or securities
directly or indirectly convertible into or exchangeable for Common Stock. 
 (e) “Date of Grant” means
October     , 2008. 
 (f) “Effective Price per share of Common Stock” means the
price of a single Convertible Security or Unit divided by the sum of (i) the number of Common Stock Equivalents underlying such Convertible Security or Unit plus (ii) the number determined by dividing (A) the number of additional
shares of Common Stock or Common Stock Equivalents that become issuable for no or nominal additional consideration in connection with the transaction in which such Convertible Securities or Units are sold due to adjustments in rates of conversion of
Convertible Securities or the like, including extraordinary issuances of securities to employees, directors or consultants in connection with the transaction, by (B) the aggregate number of shares of Common Stock and Common Stock Equivalents
underlying the Securities sold in the transaction. 
 (g) “Holder” means the initial holder of this
Warrant set forth in the first paragraph of this Warrant and any other person or entity which becomes a holder of this Warrant pursuant to the terms of this Warrant. 

 (h) “IPO” means the initial public offering of the Company’s
Common Stock effected pursuant to a registration statement on Form S-1 (or its successor) filed under the Act. 
 (i)
“Next Round Price” means the lowest Effective Price per share of Common Stock at which Securities are sold in the Company’s next Qualified Financing after the Date of Grant. 

(j) “Other Warrants” means any other warrants issued by the Company in connection with the transaction with
respect to which this Warrant was issued, and any warrant issued upon transfer or partial exercise of or in lieu of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly
requires otherwise. 
 (k) “Qualified Financing” means the sale prior to the Company’s IPO of
Securities of the Company to investors in a single transaction or a series of related transactions resulting in aggregate cash proceeds to the Company of not less than $1,000,000. 

(l) “Securities” means Common Stock, Convertible Securities or Units. 

(m) “Series C-2 Price” means $5.50 per share. 

(n) “Series Preferred” means (i)(A) the Company’s presently authorized Series C-2 Preferred Stock if Holder
exercises this Warrant for Series C-2 Preferred Stock, or (B) the type of securities sold in such Qualified Financing if Holder exercises this Warrant for the Securities sold during the next Qualified Financing, (ii) after the conversion
of all of the outstanding shares of Series Preferred Stock into Common Stock, either automatically or by vote of the requisite holders thereof, the Company’s Common Stock, or (iii) upon any conversion, exchange, reclassification or change,
any security into which the securities described in clauses (i) or (ii) of this definition may be converted, exchanged, reclassified or otherwise changed. 
 (o) “Shares” means the shares of Series Preferred of Company issuable upon exercise of this Warrant. 
 (p) “Units” means any combination of Common Stock and Convertible Securities issued by Company sold together as a single unit. 

(q) “Warrant Price” means, as it may be adjusted from time to time pursuant to Section 5, (i) the Series
C-2 Price if Holder exercises this Warrant for Series C-2 Preferred Stock, or (ii) the Next Round Price if Holder exercises this Warrant for the Securities sold during the next Qualified Financing. 

2. Term. The purchase right represented by this Warrant is exercisable, in whole or in part, at any time and from time to time from
the Date of Grant through the tenth anniversary of the Date of Grant. 
 Notwithstanding the foregoing, in the event of a
Corporate Event (as defined in Section 5(a)) where the consideration received by holders of Series Preferred in such Corporate Event is all cash, either (i) Holder shall exercise this Warrant in accordance with the terms of
Section 3(b) immediately prior to the consummation of such Corporate Event or (ii) if Holder elects not to exercise this Warrant pursuant to clause (i) of this sentence, this Warrant shall be deemed automatically exercised in
accordance with the provisions of Section 5(a)(ii) immediately prior to the consummation of the Corporate Event. 
 3.
Method of Exercise; Payment; Issuance of New Warrant; Net Issuance. 
 (a) Subject to Section 2 hereof, the purchase
right represented by this Warrant may be exercised by the Holder, in whole or in part and from time to time, at the election of the Holder, by (a) the surrender of this 

  
 -2-

 
Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the
Company, by certified or bank check, or by wire transfer to an account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased;
(b) if in connection with a registered public offering of the Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of
the Company together with notice of arrangements reasonably satisfactory to the Company for payment to the Company from the proceeds of the sale of shares to be sold by the Holder in such public offering of an amount equal to the then applicable
Warrant Price per share multiplied by the number of Shares then being purchased; or (c) exercise of the “net issuance” right provided for in Section 3(b) hereof. The person or persons in whose name(s) Shares shall be registered
upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued)
immediately prior to the close of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of this Warrant, certificates for the shares of stock so purchased shall be delivered to the Holder as soon as
possible and in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to which this Warrant shall not then
have been exercised shall also be issued to the Holder as soon as possible and in any event within such thirty-day period; provided, however, that at such time as the Company is subject to the reporting requirements of the Securities Exchange Act
of 1934, as amended, if requested by the Holder, the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to, or credit the securities account of, a broker or other person
(as directed by the Holder exercising this Warrant) within the time period required to settle any trade made by the Holder after exercise of this Warrant. 
 (b) Right to Convert Warrant into Stock: Net Issuance. 
 (i) Right to
Convert. In addition to and without limiting the rights of the Holder under the terms of this Warrant, the Holder shall have the right to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of
Series Preferred as provided in this Section 3(b) at any time or from time to time during the term of this Warrant. Upon exercise of the Conversion Right with respect to a particular number of shares subject to this Warrant (the
“Converted Warrant Shares”), the Company shall deliver to the Holder (without payment by the Holder of any exercise price or any cash or other consideration) that number of shares of fully paid and nonassessable Series
Preferred as is determined according to the following formula: 
  

															
		 		 		 		  		  	X	  	=	  	B – A
		 		 		 		  		  		  		  	   Y

													
					
		 	Where:	 	X	 	=	  	the number of shares of Series Preferred that shall be issued to Holder
					
		 		 	Y	 	=	  	the fair market value of one share of Series Preferred
					
		 		 	A	 	=	  	the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (i.e., the number of
Converted Warrant Shares multiplied by the Warrant Price)
					
		 		 	B	 	=	  	the aggregate fair market value of the specified number of Converted Warrant Shares (i.e., the number of Converted Warrant Shares multiplied by the fair
market value of one Converted Warrant Share)

 (ii) Method of Exercise. The Conversion Right may be exercised by the Holder by the surrender of
this Warrant at the principal office of the Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying that the Holder thereby intends to exercise the Conversion Right and
indicating the number of shares subject to this Warrant which are being surrendered (referred to in Section 3(b)(i) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon

  
 -3-

 
receipt by the Company of this Warrant together with the aforesaid written statement, or on such later date as is specified therein (the “Conversion Date”), and, at the
election of the Holder, may be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a registration statement under the Act (a “Public Offering”).

 (iii) Determination of Fair Market Value. For purposes of this Section 3(b), “fair market value” of a
share of Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the “Determination Date”) shall mean: 

(1) If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s registration
statement relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with
respect to such Public Offering. 
 (2) If the Conversion Right is not exercised in connection with and contingent upon a Public
Offering, then as follows: 
 (A) If traded on a securities exchange, the fair market value of the Common Stock
shall be deemed to be the average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair
market value of the Common Stock multiplied (if the Series Preferred is not then constituted as Common Stock) by the number of shares of Common Stock into which each share of Series Preferred is then convertible; 

(B) If traded on the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall
be deemed to be the average of the closing bid prices of the Common Stock over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the
Common Stock multiplied (if the Series Preferred is not then constituted as Common Stock) by the number of shares of Common Stock into which each share of Series Preferred is then convertible; and 

(C) If there is no public market for the Common Stock, then fair market value shall be reasonably determined in good faith
by the board of directors of the Company. 
 (iv) In making a determination under clauses (A) or (B) above, if on the
Determination Date, five trading days had not passed since the IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including the first
trading day after the pricing of the IPO and ending on the trading day prior to the Determination Date (or if such period includes only one trading day the closing price or closing bid price, as applicable, for such trading day). If closing prices
or closing bid prices are no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time
on the applicable trading day. 
 4. Stock Fully Paid; Reservation of Shares. All Shares that may be issued upon the
exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the issue thereof.
During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this Warrant, a
sufficient number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and, while applicable, a sufficient number of shares of its Common Stock to provide for the conversion of the Series Preferred
into Common Stock. 

  
 -4-

 5. Adjustment of Warrant Price and Number of Shares. The number and kind of
securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 

(a) Corporate Events. 
 (i) In case of any reclassification or change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value
to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another corporation (other than a merger with another corporation in which the Company is the acquiring and the surviving corporation
and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant) (each, a “Corporate Event”), the Company, or such successor corporation, as the case may be, shall
duly execute and deliver to the Holder a new Warrant (in form and substance satisfactory to the Holder), or the Company shall make appropriate provision without the issuance of a new Warrant, so that the Holder shall have the right to receive upon
exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon exercise of this Warrant, the kind
and amount of shares of stock, other securities, money and property receivable upon such Corporate Event by a holder of the number of shares of Series Preferred then purchasable under this Warrant. Any new Warrant shall provide for adjustments that
shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 5. The provisions of this Section 5(a)(i) shall similarly apply to successive Corporate Events. 

(ii) Notwithstanding anything to the contrary set forth in Section 5(a)(i), in the event of a Corporate Event, any sale of all or
substantially all of the assets of the Company or an IPO, in which Holder has not exercised this Warrant in accordance with the terms of either Sections 3(a) or 3(b) above, at Holder’s option, immediately prior to the consummation of such
Corporate Event, Holder may elect to surrender this Warrant to the Company in exchange for a cash payment in an amount equal to the product of (x) two (2) times the Warrant Price then in effect and (y) the number of shares of Series
Preferred issuable pursuant to the terms hereof had Holder elected to exercise this Warrant immediately prior to the consummation of such Corporate Event. 
 (b) Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Series Preferred, the
Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Shares issuable
hereunder shall be proportionately decreased in the case of a combination. 
 (c) Stock Dividends and Other Distributions.
If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay a dividend with respect to Series Preferred payable in Series Preferred, then the Warrant Price shall be adjusted, from and after the date of determination
of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total
number of shares of Series Preferred outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Series Preferred outstanding immediately after such dividend or
distribution; or (ii) make any other distribution with respect to Series Preferred (except any distribution specifically provided for in Sections 5(a) and 5(b)), then, in each such case, provision shall be made by the Company such that the
Holder shall receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the
determination of the shareholders of the Company entitled to receive such dividend or distribution. 
 (d) Adjustment of
Number of Shares. Upon each adjustment in the Warrant Price, the number of Shares of Series Preferred purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable
immediately prior to such adjustment in the Warrant Price by a 

  
 -5-

 
fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 

(e) Antidilution Rights. The other antidilution rights applicable to the Shares of Series Preferred purchasable hereunder are set
forth in the Company’s Certificate of Incorporation, as amended through the Date of Grant, a true and complete copy of which is attached hereto as Exhibit B (the “Charter”). If the Company proposes a restatement,
amendment, modification or waiver of antidilution rights that treats the Holder disproportionately in an adverse manner than the other holders of the Shares of Series Preferred purchasable hereunder with respect to such antidilution rights, then
such restatement, amendment, modification or waiver shall require the consent of the Holder. The Company shall promptly provide the Holder with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made.

 6. Notice of Adjustments. Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted
pursuant to Section 5 hereof, the Company shall deliver to Holder a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which
such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment. In addition, whenever the conversion price or conversion ratio of the Series Preferred shall be adjusted,
the Company shall deliver to Holder a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and
the conversion price or ratio of the Series Preferred after giving effect to such adjustment. Whenever the Warrant Price or the number of Shares purchasable hereunder shall be fixed according to a formula based upon the occurrence of an event or
events subsequent to the Date of Grant, at the end of the period during which the event or events can occur, the Company shall deliver to Holder a certificate signed by its chief financial officer setting forth the Warrant Price and/or number of
Shares purchasable hereunder, and, in reasonable detail, the calculation of the Warrant Price and/or such number of Shares. 
 7.
Fractional Shares. No fractional shares of Series Preferred will be issued in connection with any exercise or conversion hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on the fair market
value of the Series Preferred on the date of exercise or conversion as reasonably determined in good faith by the Company’s Board of Directors. 
 8. Compliance with Act; Disposition of Warrant or Shares of Series Preferred. 
 (a) Compliance with Act. The Holder, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred to be issued upon exercise hereof and any Common Stock issued upon conversion
thereof are being acquired for investment and that the Holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred to be issued upon exercise hereof or any Common Stock issued upon conversion thereof except
under circumstances which will not result in a violation of the Act or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an
exemption from such registration is available, the Holder shall confirm in writing that the shares of Series Preferred so purchased (and any Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward
distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company. This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all Common
Stock issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be stamped or imprinted with a legend in substantially the following form: 

“THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE
OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED,
(iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF 

  
 -6-

 
SECTION 8 OF THE WARRANT UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.” 
 Said legend shall be removed by the Company, upon the request of the Holder, at such time as the restrictions on the transfer of the applicable security shall have terminated. In addition, in connection
with the issuance of this Warrant, the Holder specifically represents to the Company by acceptance of this Warrant as follows: 

(1) The Holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company
sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The Holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any
“distribution” thereof in violation of the Act. 
 (2) The Holder understands that this Warrant has not been
registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. 

(3) The Holder further understands that this Warrant and the Series Preferred must be held indefinitely unless subsequently registered
under the Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The Holder is aware of the provisions of Rule 144, promulgated under the Act. 

(4) The Holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the
Act. 
 (b) Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any
shares of Series Preferred acquired pursuant to the exercise of this Warrant, the Holder agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of counsel, or other
evidence, if reasonably satisfactory to the Company, to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in
effect) of this Warrant or such shares of Series Preferred or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or otherwise disposed of require any restrictive
legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company, as promptly as practicable but no later than
fifteen (15) days after receipt of the written notice, shall notify the Holder that the Holder may sell or otherwise dispose of this Warrant or such shares of Series Preferred or Common Stock, all in accordance with the terms of the notice
delivered to the Company. If a determination has been made pursuant to this Section 8(b) that the opinion of counsel or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the Holder promptly with details
thereof after such determination has been made. Notwithstanding the foregoing, this Warrant or such shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of (i) pursuant to an effective
registration statement covering such securities or (ii) in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished with such information as the Company may reasonably request to provide a
reasonable assurance that the provisions of Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the shares of Series Preferred thus transferred (except a transfer pursuant to an effective registration statement
or Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the Holder, such legend is not required in order to
ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 
 (c) Applicability of Restrictions. Neither any restrictions of any legend described in this Warrant nor the requirements of Section 8(b) above shall apply to any transfer of, or grant of a
security interest in, this Warrant (or the Series Preferred or Common Stock obtainable upon exercise thereof) or any part hereof (i) to a partner of the Holder if the Holder is a partnership or to a member of the Holder if the Holder is a
limited liability company, (ii) to a 

  
 -7-

 
partnership of which the Holder is a partner or to a limited liability company of which the Holder is a member, or (iii) to a single affiliate of the Holder if the Holder is a corporation,
where, in each case, the transferee is an “accredited investor”. In any such transfer described in this Section 8(c), if applicable, the transferee shall on the Company’s request agree in writing to be bound by the terms of this
Warrant as if an original holder hereof. 
 9. Rights as Shareholders; Information. No Holder, as a holder of this
Warrant, shall be entitled to vote or receive dividends or be deemed the holder of Series Preferred or any other securities of the Company which may at any time be issuable upon the exercise or conversion hereof for any purpose, nor shall anything
contained herein be construed to confer upon the Holder, as such, any of the rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to receive
notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised or converted and the Shares purchasable upon the exercise or conversion hereof shall have become deliverable, as provided
herein. Notwithstanding the foregoing, the Company will transmit to the Holder such information, documents and reports as are generally distributed to the holders of Series Preferred or Common Stock concurrently with the distribution thereof to the
shareholders. In addition, the Company agrees to provide in a timely manner any information reasonably requested by the Holder to enable the Holder and its affiliates to comply with their accounting reporting requirements. 

10. Market Stand-Off Agreement. Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the
purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by Holder (other than those included in the registration), for a period of time
specified by the managing underwriter(s) (not to exceed one hundred eighty (180) days) (or such longer period as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 so long as the investors party
to the Registration Rights Agreement (as defined below) are also subject to such extension) following the effective date of a registration statement of the Company filed under the Act. Holder agrees to execute and deliver such other agreements as
may be reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 10 and shall have the right,
power and authority to enforce the provisions hereof as though they were a party hereto. 
 11. Registration Rights. The
Company grants registration rights to the Holder of this Warrant for any Common Stock of the Company obtained upon conversion of the Series Preferred, the registration rights granted to the investors in that certain Amended and Restated
Investors’ Rights Agreement dated as of December 11, 2007, (as may be amended from time to time, the “Registration Rights Agreement”), with the following exceptions and clarifications: 

(a) The Holder will only participate in a “piggyback” registration demanded by others, but will not have the right to demand
registration. 
 (b) The Holder will be subject to the same provisions, including regarding indemnification, as contained in the
Registration Rights Agreement. 
 (c) The registration rights are freely assignable by the Holder of this Warrant in connection
with a permitted transfer of this Warrant or the Shares. 
 12. Additional Rights. 

(a) Acquisition Transactions. The Company shall provide the Holder with at least twenty (20) days’ written notice prior
to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof): (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the Company’s
property or business, or (ii) its merger into or consolidation with any other corporation (other than a 

  
 -8-

 
wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the
Company is disposed of. In addition, in the event the Company proposes to enter into a Corporate Event, any sale of all or substantially all of the assets of the Company or an IPO, the Company shall provide the Holder with at least twenty
(20) days’ written notice prior to closing thereof of the terms and conditions of such event and specifying that Holder may elect to (i) exercise its purchase right in accordance with the provisions of Section 3(a) hereof, if
applicable, (ii) exercise its Conversion Right in accordance with the provisions of Section 3(b) hereof, (iii) receive a new Warrant or receive appropriate provisions without the issuance of a new Warrant in accordance with the
provisions of Section 5(a)(i) hereof, if applicable, (iv) surrender this Warrant in exchange for cash payment in accordance with the provisions of Section 5(a)(ii) hereof, or (v) allow this Warrant to continue in effect until
this Warrant is exercised pursuant to the terms hereof or expires, if applicable. 
 (b) Exercise Prior to Expiration. To
the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall be deemed
automatically exercised pursuant to Section 3(b) above (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Series Preferred upon such expiration shall
be determined pursuant to Section 3(b). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 12(b), the Company agrees to promptly notify the Holder of the number of Shares, if any,
the Holder is to receive by reason of such automatic exercise. 
 13. Representations and Warranties. The Company
represents and warrants to the Holder as follows: 
 (a) This Warrant has been duly authorized and executed by the Company and is
a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing
specific performance, injunctive relief and other equitable remedies. 
 (b) The Shares have been, or will be prior to the
exercise of this Warrant, duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable and free from preemptive rights. 

(c) The rights, preferences, privileges and restrictions granted to or imposed upon the Series Preferred and the holders thereof are, or,
in the case of a Qualified Financing, will be prior to the exercise of this Warrant, as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is convertible into one share of Common Stock.

 (d) The shares of Common Stock issuable upon conversion of the Shares have been, or will be prior to the exercise of this
Warrant, duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable. 

(e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with
the terms hereof will not be, inconsistent with the Company’s Charter or by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or
contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the
registration or filing with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings
will be effected by the time required thereby. 
 (f) There are no actions, suits, audits, investigations or proceedings pending
or, to the knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or 

  
 -9-

 
authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform its obligations under this Warrant. 

(g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted basis (assuming the conversion
of all outstanding convertible securities and the exercise of all outstanding options and warrants), does not exceed 24,000,000 shares. 
 14. Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of
the same is sought. 
 15. Notices. Any notice, request, communication or other document required or permitted to be given
or delivered to the Holder or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to the Holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on
the signature page of this Warrant. Such notice, request, communication or other document may also be delivered by any other means of transmission so long as reasonable confirmation of receipt by the addressee is obtained. 

16. Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger,
consolidation or acquisition of all or substantially all of the Company’s assets, and all of the obligations of the Company relating to the Series Preferred issuable upon the exercise or conversion of this Warrant shall survive the exercise,
conversion and termination of this Warrant and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the Holder. 
 17. Lost Warrants or Stock Certificates. The Company covenants to the Holder that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant
or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 

18. Descriptive Headings. The descriptive headings of the various Sections of this Warrant are inserted for convenience only and do
not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant. 
 19. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California. 

20. Survival of Representations, Warranties and Agreements. All representations and warranties of the Company and the Holder
contained herein and made as of the Date of Grant shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All agreements of the Company and the Holder
contained herein shall survive indefinitely until, by their respective terms, they are no longer operative. 
 21.
Remedies. In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the Holder (in the case of a breach by the Company), or the Company (in the case of a breach by the Holder), may proceed to
protect and enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement
contained in this Warrant. 
 22. Severability. The invalidity or unenforceability of any provision of this Warrant in any
jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect. 

  
 -10-

 23. Recovery of Litigation Costs. If any legal action or other proceeding is brought
for the enforcement of this Warrant, or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover
reasonable attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it or they may be entitled. 
 24. Entire Agreement. This Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements,
representations, and undertakings of the parties, whether oral or written, with respect to such subject matter. 

  
 -11-

 The Company has caused this Warrant to be duly executed and delivered as of the Date of
Grant specified above. 
  

			
	REVANCE THERAPEUTICS, INC.
		
	By	 	 
		
	Title	 	  

		
	Address:	 	

  
 -12-

 Execution 

EXHIBIT A-1 

NOTICE OF EXERCISE 
  

	To:	REVANCE THERAPEUTICS, INC. (the “Company”) 

  

	 	1.	The undersigned hereby: 

  

	 	 ̈	elects to purchase            shares of [Series Preferred Stock] of the Company pursuant to the terms of the
attached Warrant, and tenders herewith payment of the purchase price of such shares in full, or 

  

	 	 ̈	elects to exercise its net issuance rights pursuant to Section 3(b) of the attached Warrant with respect
to            Shares of [Series Preferred Stock]. 

 2.
Please issue a certificate or certificates representing             shares in the name of the undersigned or in such other name or names as are specified below: 

 

					
		  	  
	  	
		  	(Name)	  	
		  	  
	  	
		  	  
	  	
		  	(Address)	  	

 3. The undersigned represents that the aforesaid shares are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable
securities laws. 
  

	
	  
	(Signature)

  

			
	  
	  	
	    (Date)	  	

 EXHIBIT A-2 
 NOTICE OF EXERCISE 
  

	To:	REVANCE THERAPEUTICS, INC. (the “Company”) 

 1. Contingent upon and effective immediately prior to the closing (the “Closing”) of the Company’s public offering contemplated by the Registration Statement on
Form S            , filed            , 200__, the undersigned hereby: 

 ̈ elects to
purchase            shares of [Series Preferred Stock] of the Company (or such lesser number of shares as may be sold on behalf of the undersigned at the Closing) pursuant to the terms of
the attached Warrant, or 
  ̈ elects to exercise its net issuance rights pursuant
to Section 3(b) of the attached Warrant with respect to            Shares of [Series Preferred Stock]. 
 2. Please deliver to the custodian for the selling shareholders a stock certificate representing such            shares. 

3. The undersigned has instructed the custodian for the selling shareholders to deliver to the Company
$            or, if less, the net proceeds due the undersigned from the sale of shares in the aforesaid public offering. If such net proceeds are less than the purchase price for such
shares, the undersigned agrees to deliver the difference to the Company prior to the Closing. 
  

	
	  
	(Signature)

  

			
	  
	  	
	        (Date)	  	

 EXHIBIT B 
 CHARTEREX-10.31

 Exhibit 10.31 
 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED. 

REVANCE THERAPEUTICS, INC. 
 WARRANT TO PURCHASE SERIES D PREFERRED STOCK 
  

			
	No. PWD-        	  	June         , 2010

 THIS CERTIFIES THAT, for value
received, ESSEX CAPITAL CORPORATION, with its principal office at 1486 East Valley Road, 2nd Floor, Santa Barbara, California 93108, or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined
below) from Revance Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal office at 7555 Gateway Boulevard, Newark, California 94560, the Exercise Shares (defined below). 

1. DEFINITIONS. As used herein, the following terms shall have the following respective meanings: 

(a) “Exercise Period” shall mean the period commencing with the date of this warrant and on the Expiration Date, unless
terminated earlier in accordance with the terms hereof. 
 (b) “Exercise Price” shall mean four dollars and
forty five cents ($4.45) per Exercise Share; provided further that the Exercise Price is subject to further adjustment pursuant to Section 5 below. 
 (c) “Exercise Shares” shall mean (i) up to 47,191 shares of the Company’s Series D Preferred Stock (the “Series D Stock”), or (ii) if all outstanding Series D
Stock has been automatically converted pursuant to Section 5 of the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), that number of shares of common stock of the
Company, par value $0.001 per share (the “Common Stock”), into which the Series D Stock would have been converted immediately prior to such date of exercise, subject to further adjustment pursuant to Section 5 below. 

(d) “Expiration Date” shall mean the date nine years after the date hereof. 

(e) “Investor Rights Agreement” shall mean the Amended and Restated Investor Rights Agreement dated December 8,
2009, among the Company and the investors named therein, as further amended from time to time. 
 2. EXERCISE
OF WARRANT. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following 

  
 1. 

 
to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

(a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price either (i) in cash or by check, (ii) by cancellation of indebtedness,
(iii) through a net exercise pursuant to Section 2.1 below; and 
 (c) This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased,
registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised.
In the event the Warrant is not exercised in full, the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder may request,
exercisable for the number of Exercise Shares equal (without giving effect to any adjustment therein) to the total number of such Exercise Shares for which this Warrant is then exercisable minus the number of Exercise Shares (without giving effect
to any adjustment therein) for which this Warrant shall have been exercised. 
 The person or entity in whose name any
certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was
made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the
holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open. 
 2.1
Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment
of cash, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed
Notice of Exercise in which event the Company shall issue to the Holder a number of Exercise Shares computed using the following formula: 
  

													
		 		 		 		  	X	  	=	  	Y (A-B)
		 		 		 		  		  		  	       A
					
		 	Where	 	X	 	=	  	the number of Exercise Shares to be issued to the Holder
					
		 		 	Y	 	=	  	the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the
date of such calculation)
					
		 		 	A	 	=	  	the fair market value of one Exercise Share (at the date of such calculation)

  
 2. 

													
					
		 		 	B	 	=	  	Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation, prior to the Company’s initial public offering of its Common
Stock (“IPO”), the fair market value of one Exercise Share shall be determined by the Company’s Board of Directors in good faith. If this Warrant is exercised pursuant to this Section 2.1 in connection with the Company’s
IPO, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of Common Stock into which each Exercise Share is
convertible at the time of such exercise. If this Warrant is exercised after the Company’s IPO, the fair market value per share shall be determined as follows: 
 (i) if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five (5) day period ending three (3) days before
the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each Exercise Share is convertible at the time of such exercise; 

(ii) if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and
asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common
Stock into which each Exercise Share is convertible at the time of such exercise; or 
 (iii) if not listed on any
securities exchange or quoted in the NASDAQ System or the over-the-counter market, the fair market value shall be determined in good faith by the Company’s Board of Directors. 

2.2 Exercise in Connection with Public Offering. Notwithstanding anything to the contrary herein, if an exercise of any portion of
this Warrant is to be made in connection with a registered public offering or the sale of the Company, the exercise of this Warrant may, at the election of the Holder, be conditioned upon the consummation of the public offering or sale of the
Company, in which case such exercise shall be deemed to not be effective unless and until such transaction is consummated. 

3. COVENANTS OF THE COMPANY. 

3.1 Exercise Shares. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the
Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of this Warrant, and free from pre-emptive rights, a number of Exercise Shares equal to the total number of Exercise Shares from time to time
issuable upon exercise of this Warrant, and, from time to time, will take all steps necessary to amend its Certificate of Incorporation to provide sufficient reserves of Exercise Shares issuable upon exercise of this Warrant. 

  
 3. 

 3.2 Shareholder Rights. The Company covenants and agrees that, in the event that the
Holder receives Series D Stock upon exercise of this Warrant, the Holder shall have the same rights that are afforded to other holders of the Series D Stock, including all of those rights contained in the Investor Rights Agreement applicable to
Holder based upon the number of shares of Series D Stock held by Holder and subject to other conditions and limitations set forth therein, provided that the Holder joins as a party to the Investor Rights Agreement. 

4. REPRESENTATIONS OF HOLDER. 

4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant and the
Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the entire legal and beneficial interests of the Warrant
and Exercise Shares the Holder is acquiring is being acquired for its account only. 
 4.2 Securities Are Not
Registered. 
 (a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the
Securities Act of 1933, as amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding
its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing
the securities. The Holder has no such present intention. 
 (b) The Holder recognizes that the Warrant and the Exercise
Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of
the Company, or to comply with any exemption from such registration, except as may be provided for the Investor Rights Agreement. 
 (c) The Holder is aware that neither the Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the
availability of certain current public information about the Company, the resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is
aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 

4.3 Disposition of Warrant and Exercise Shares. 
 (a) The Company and the Holder agree that the Warrant and the Exercise Shares will be subject to the restrictions on transfer set forth in Section 2.1 of the Investor Rights Agreement.

 (b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear
the following legend: 

  
 4. 

 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED. 
 4.4 Accredited Investor Status. The Holder is an “accredited investor” as defined in Regulation
D promulgated under the Act. 
 5. ADJUSTMENT OF EXERCISE
PRICE. 
 5.1 Changes in Securities. In the event of changes in the outstanding Series D Stock of the
Company by reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, consolidation, merger, liquidations, or the like, the number and class of shares available under
the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned
had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall
terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

5.2 Continuation of Terms. Subject to Section 7, upon any reorganization, consolidation or merger (and any liquidation
following any such event) referred to in this Section 5, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the shares of stock and other securities and property receivable on the exercise of this
Warrant after the consummation of such reorganization, consolidation or merger, or the effective date of liquidation following any such event, as the case may be, and shall be binding upon the issuer of any stock or other securities in such event,
whether or not such person shall have expressly assumed the terms of this Warrant. 
 6. FRACTIONAL
SHARES. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated
for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional
share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

7. EARLY TERMINATION. In the event of (a) any capital reorganization, or the consolidation or
merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the Company (in the 

  
 5. 

 
aggregate) immediately prior to such consolidation, merger or reorganization, own less than fifty percent (50%) of the voting power of the surviving entity immediately after such
consolidation, merger or reorganization, (b) any transaction or series of related transactions to which the Company is a party in which in excess of fifty percent (50%) of the Company’s voting power is transferred, or (c) sale or
other disposition of all or substantially all the assets of the Company (each, an “Acquisition Event”), in which the consideration paid to the Company or its stockholders consists of cash and/or publicly traded securities, then the Company
shall provide to the Holder ten (10) days advance notice of such Acquisition Event, and this Warrant shall terminate unless exercised prior to the consummation of the Acquisition Event. 

8. MARKET STAND-OFF AGREEMENT. Holder agrees that the market stand-off
agreement in Section 2.11 of the Investor Rights Agreement shall apply to the Warrant and the Exercise Shares. 
 9.
NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. 

10. LOST, STOLEN, MUTILATED OR DESTROYED
WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the
surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly
lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 11. NOTICES,
ETC. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by telex, telegram, express mail or other form of rapid communications, if possible, and if not then such notice or
communication shall be mailed by first-class mail, postage prepaid, addressed in each case to the party entitled thereto at the following addresses: (a) if to the Company, to Revance Therapeutics, Inc., Attention: Chief Financial Officer, 7555
Gateway Boulevard, Newark, CA 94560 and (b) if to the Holder, to the address stated herein, or at such other address as one party may furnish to the other in writing. Notice shall be deemed effective on the date dispatched if by personal
delivery, telecopy, telex or telegram, two days after mailing if by express mail, or three days after mailing if by first-class mail. In the event of any Acquisition Event, the Company shall provide to the Holder ten (10) days advance notice of
such Acquisition Event. 
 12. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. 
 13. GOVERNING
LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed
entirely within the State of California without giving effect to conflicts of laws principles. 

  
 6. 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of June     , 2010. 
  

			
	REVANCE THERAPEUTICS, INC.
		
	By:	 	 
		 	David Styka, Chief Financial Officer

  
 7. 

 NOTICE OF EXERCISE 
 TO: REVANCE THERAPEUTICS, INC. 

(1)      ̈ The undersigned hereby elects to purchase
            shares of              of Revance Therapeutics, Inc. (the “Company”) pursuant
to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full. 
  ̈ The undersigned hereby elects to purchase              shares of              the
Company pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the attached Warrant. 

(2)    Please issue a certificate or certificates representing said shares of stock in the name of the
undersigned or in such other name as is specified below: 
  

							
		  	  
	  	  
	  	
		  	            (Name)	  	  
	  	
		  		  	(Address)	  	

 (3) The undersigned represents that (i) the aforesaid shares are being acquired for the
account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is
aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) undersigned is
experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own
interests; (iv) undersigned understands that the shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the
registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they
must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) undersigned is aware that the aforesaid shares may not be sold pursuant to Rule 144 adopted under the
Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public
about the Company and the Company has not made such information available and has no present plans to do so; (vi) undersigned agrees not to make any disposition of all or any part of the aforesaid shares unless and until there is then in effect
a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to
the Company, stating that such registration is not required; and (vii) undersigned agrees to continue to be bound by the terms of the Warrant, including the market stand-off agreement in Section 8. 

 

									
	Date:	 	 	 		 	By:	 	 
					
		 		 		 	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]